Find News

Filter articles

Applied Filters

Showing 21 to 30 of 706 results

Alphabet's Verily in digital research alliance with Pfizer and others


Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes.

Genentech enters agreement to develop autoimmune therapies


US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.

Google fund invests in CRISPR start-up


Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.

Diabetics to benefit under latest FDA biosimilar guidance


The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Federal Circuit backs Sandoz in Amgen biosimilar suit


The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.

Lundbeck to acquire Abide Therapeutics for $250 million


Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.

Bayer CropScience accuses ex-employee of trade secret theft


A former scientist at Bayer CropScience shared confidential information with his new employer, which was used to develop commercial biopesticide products, according to a claim filed by the agricultural company.

Clint Eastwood’s patent lawsuit dismissed


A judge has dismissed actor Clint Eastwood’s motion to gain ownership over two diabetes patents currently assigned to Molecular Defenses Corporation.

Amgen and Roche target Samsung’s Bioepis in patent suit


Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

Sandoz and EirGenix to market Herceptin biosimilar

EU, Taiwan01-05-2019

A division of Novartis has entered into an agreement with Taiwan-based EirGenix to market a medicine which treats some cancer tumours.

Showing 21 to 30 of 706 results